196 related articles for article (PubMed ID: 15563316)
1. Balancing risks and benefits in pain medicine: wither Vioxx.
Gallagher RM
Pain Med; 2004 Dec; 5(4):329-30. PubMed ID: 15563316
[No Abstract] [Full Text] [Related]
2. [Really only Vioxx?].
Heinzl S
Med Monatsschr Pharm; 2004 Nov; 27(11):361. PubMed ID: 15566229
[No Abstract] [Full Text] [Related]
3. Vioxx doctors wooed by Merck are now its foes.
Tesoriero HW
Wall St J (East Ed); 2006 Mar; ():B1, B3. PubMed ID: 16578911
[No Abstract] [Full Text] [Related]
4. Anticipating a Vioxx defense strategy: will corporate honesty be enough?
Willis KD
Tort Trial Insur Pract Law J; 2006; 41(4):1163-78. PubMed ID: 17091567
[No Abstract] [Full Text] [Related]
5. Life after Vioxx.
Underwood A
Newsweek; 2005 Jan; 145(5):40-1. PubMed ID: 17896720
[No Abstract] [Full Text] [Related]
6. Learning the value of drugs--is rofecoxib a regulatory success story?
Eisenberg RS
N Engl J Med; 2005 Mar; 352(13):1285-7. PubMed ID: 15800222
[No Abstract] [Full Text] [Related]
7. Drug safety. Withdrawal of Vioxx casts a shadow over COX-2 inhibitors.
Couzin J
Science; 2004 Oct; 306(5695):384-5. PubMed ID: 15486258
[No Abstract] [Full Text] [Related]
8. Health Canada lukewarm on Vioxx panel findings.
Murray S
CMAJ; 2005 Aug; 173(4):350. PubMed ID: 16103502
[No Abstract] [Full Text] [Related]
9. The lessons of Vioxx--drug safety and sales.
Waxman HA
N Engl J Med; 2005 Jun; 352(25):2576-8. PubMed ID: 15972862
[No Abstract] [Full Text] [Related]
10. [The rise and fall of Vioxx: society, values and their choice].
Caspi D
Harefuah; 2004 Nov; 143(11):770-1. PubMed ID: 15603261
[No Abstract] [Full Text] [Related]
11. Was Vioxx really that dangerous?
Park A
Time; 2005 Feb; 165(9):52. PubMed ID: 15765852
[No Abstract] [Full Text] [Related]
12. Rofecoxib (Vioxx) withdrawal: do product monographs adequately inform physicians?
Can Fam Physician; 2005 Feb; 51(2):212-3. PubMed ID: 15751564
[No Abstract] [Full Text] [Related]
13. How to avoid another 'Vioxx'.
Frantz S
Nat Rev Drug Discov; 2005 Jan; 4(1):5-7. PubMed ID: 15690595
[No Abstract] [Full Text] [Related]
14. [VIOXX written off--and what next? COX-2 inhibitors and cardiovascular diseases].
Jerie P
Cas Lek Cesk; 2005; 144(1):4. PubMed ID: 15789774
[No Abstract] [Full Text] [Related]
15. COX-2 inhibitor use after Vioxx: careful balance or end of the rope?
Fendrick AM
Am J Manag Care; 2004 Nov; 10(11 Pt 1):740-1. PubMed ID: 15623263
[No Abstract] [Full Text] [Related]
16. [General practice study of therapy of acute pain. Patients prefer cox-2 inhibitors].
MMW Fortschr Med; 2004 May; 146(21):61. PubMed ID: 15373091
[No Abstract] [Full Text] [Related]
17. Causation, Vioxx, and legal issues.
Green MD
Science; 2005 Nov; 310(5750):973. PubMed ID: 16284163
[No Abstract] [Full Text] [Related]
18. Will Merck survive Vioxx?
Simons J; Stipp D
Fortune; 2004 Nov; 150(9):90-2, 94, 96-7 passim. PubMed ID: 15543824
[No Abstract] [Full Text] [Related]
19. [Vision impairment by COX-2 inhibitor and the sequelae of voluntary Vioxx recall].
Meyer CH
Klin Monbl Augenheilkd; 2005 Jan; 222(1):62-3. PubMed ID: 15678404
[No Abstract] [Full Text] [Related]
20. [Could Vioxx have been recalled earlier?].
Moan A
Tidsskr Nor Laegeforen; 2005 Feb; 125(3):323-4. PubMed ID: 15702160
[No Abstract] [Full Text] [Related]
[Next] [New Search]
